Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 20, 2024 - Issue 1
Submit an article Journal homepage
686
Views
0
CrossRef citations to date
0
Altmetric
Immunotherapy - Cancer

Long survival after neoadjuvant and adjuvant camrelizumab plus chemotherapy and surgery in a patient with hepatoid adenocarcinoma of the lung: A case report

Xuhua Huanga Department of Thoracic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaView further author information
,
Linhai Zhua Department of Thoracic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaView further author information
,
Weifeng Panb Department of Radiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaView further author information
&
Jian Hua Department of Thoracic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China;c Key Laboratory of Clinical Evaluation Technology for Medical Device of Zhejiang Province, Hangzhou, ChinaCorrespondence[email protected]
View further author information
Article: 2342133 | Received 27 Aug 2023, Accepted 09 Apr 2024, Published online: 24 Apr 2024

References

  • Bonis A, Dell’amore A, Verzeletti V, Melan L, Zambello G, Nardocci C, Comacchio GM, Pezzuto F, Calabrese F, Rea F, et al. Hepatoid adenocarcinoma of the lung: a review of the most updated literature and a presentation of three cases. J Clin Med. 2023;12(4):12. doi:10.3390/jcm12041411.
  • Chen Z, Ding C, Zhang T, He Y, Jiang G. Primary hepatoid adenocarcinoma of the lung: a systematic literature review. Onco Targets Ther. 2022;15:609–4. doi:10.2147/OTT.S364465.
  • Hiroshima K, Iyoda A, Toyozaki T, Haga Y, Baba M, Fujisawa T, Ishikura H, Ohwada H. Alpha-fetoprotein-producing lung carcinoma: report of three cases. Pathol Int. 2002;52:46–53. doi:10.1046/j.1440-1827.2002.01311.x.
  • Chen L, Han X, Gao Y, Zhao Q, Wang Y, Jiang Y, Liu S, Wu X, Miao L. Anti-PD-1 therapy achieved disease control after multiline chemotherapy in unresectable KRAS-Positive hepatoid lung adenocarcinoma: a case report and literature review. Onco Targets Ther. 2020;13:4359–4364. doi:10.2147/OTT.S248226.
  • Chen HF, Wang WX, Li XL, Xu CW, Du KQ, Zhu YC, Fang M-Y. Hepatoid adenocarcinoma of the lung with EGFR mutation and the response to Tyrosine Kinase inhibitors. J Thorac Oncol. 2019;14:217–219. doi:10.1016/j.jtho.2019.04.032.
  • Hou X, Shi X, Luo J. Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer. Oncol Lett. 2022;24:215. doi:10.3892/ol.2022.13336.
  • Markham A, Keam SJ. Camrelizumab: first global approval. Drugs. 2019;79:1355–1361. doi:10.1007/s40265-019-01167-0.
  • Yao Y, Guan X, Bao G, Liang J, Li T, Zhong X. Whole-exome sequencing and bioinformatics analysis of a case of non-alpha-fetoprotein-elevated lung hepatoid adenocarcinoma. Front Pharmacol. 2022;13:945038. doi:10.3389/fphar.2022.945038.
  • Haninger DM, Kloecker GH, Bousamra Ii M, Nowacki MR, Slone SP. Hepatoid adenocarcinoma of the lung: report of five cases and review of the literature. Mod Pathol. 2014;27(4):535–542. doi:10.1038/modpathol.2013.170.
  • Hou Z, Xie J, Zhang L, Dai G, Chen Y, He L. Hepatoid Adenocarcinoma of the lung: a systematic review of the literature from 1981 to 2020. Front Oncol. 2021;11:702216. doi:10.3389/fonc.2021.702216.
  • Lei J, Zhao J, Gong L, Ni Y, Zhou Y, Tian F, Liu H, Gu Z, Huang L, Lu Q, et al. Neoadjuvant Camrelizumab plus platinum-based chemotherapy vs chemotherapy alone for Chinese patients with resectable stage IIIA or IIIB (T3N2) non–small cell lung cancer. JAMA Oncol. 2023;9:1348–1355. doi:10.1001/jamaoncol.2023.2751.
  • Basse V, Schick U, Guéguen P, Le Maréchal C, Quintin-Roué I, Descourt R, Simon H, Uguen A, Quéré G. A mismatch repair–deficient hepatoid adenocarcinoma of the lung responding to anti–PD-L1 durvalumab therapy despite no PD-L1 expression. J Thorac Oncol. 2018;13:120–122. doi:10.1016/j.jtho.2018.03.004.
  • Li Y, Liu L, Wang D, Tan X, Sui Y, Yang H. Hepatoid adenocarcinoma of the lung with PD-L1 expression and the response to anti-PD-1 therapy: a case report. Front Oncol. 2023;13:1257931. doi:10.3389/fonc.2023.1257931.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.